Tuesday, January 10, 2006

Arimidex (Anastrozole) more effective than Tamoxifen for post-menopausal, early-stage ER+ Breast Cancer

XagenaMedicine (via AstraZeneca), January 10, 2005
Data presented at the San Antonio Breast Cancer Symposium found that by replacing Tamoxifen with Arimidex (an aromatase inhibitor), postmenopausal women being treated for hormone-receptive, early breast cancer may almost halve the likelihood of their disease returning and reduce their risk of dying by nearly a third. "The ATAC trial has confirmed that starting treatment with Anastrozole at the earliest opportunity after surgery, and giving it for the full five years of treatment, is more effective than Tamoxifen for the prevention of disease recurrence. This would suggest that the best place to use Anastrozole is right from the start. These new data are important news for women currently taking Tamoxifen who can still gain from the significant benefits of anastrozole by switching at two years," commented Jeffrey Tobias of the University College London Hospitals, London ( UK ). --Click the title of this post to read the full article from its source--

1 Comments:

At January 13, 2006 3:50 PM, Ali said...

It is amazing the number of drugs and things they are using to combat cancer now days.

 

Post a Comment

<< Home

/* WebRing Code */